Skip to main content
. Author manuscript; available in PMC: 2022 Jan 18.
Published in final edited form as: Leukemia. 2021 Jul 29;36(1):68–79. doi: 10.1038/s41375-021-01346-7

Figure 2: Igf2bp3 deletion delays leukemogenesis and reduces disease severity.

Figure 2:

a) Leukemia-free survival of mice transplanted with control (Ctrl) or MLL-Af4 transduced HSPCs from WT or Igf2bp3 KO mice (Kaplan-Meier method with Log-rank test; ****P < 0.0001).

b) Overall survival of mice transplanted with Ctrl or MLL-Af4 transduced HSPCs from WT or I3KO mice (n=12 WT/Ctrl, n=24 WT/MLL-Af4, n=7 I3KO/Ctrl, n=22 I3KO/MLL-Af4; Kaplan-Meier method with Log-rank test; ****P < 0.0001).

c) Time course of WBC in the PB of mice transplanted with Ctrl or MLL-Af4 transduced HSPCs from WT or I3KO mice (Data represented as means of three experiments; n=4 Ctrl, n=8 MLL-Af4 per experiment).

d) Spleen weights of mice transplanted with Ctrl or MLL-Af4 transduced HSPCs from WT or I3KO mice at 14 weeks (n=4 Ctrl, n=8 MLL-Af4; one-way ANOVA followed by Bonferroni’s multiple comparisons test; ****P < 0.0001).

e) H&E staining of liver and spleen of mice transplanted with mice transplanted with MLL-Af4 transduced HSPCs from WT or I3KO mice at 14 weeks. Scale bar:100 microns; CV=Central vein; W=White pulp; R=Red pulp; Leu= Leukemia; arrows showing infiltration.

f) Quantitation of CD11b+Ki67+ cells in the spleen at 14 weeks post-transplantation (n= 4 Ctrl, n=8 MLL-Af4; one-way ANOVA followed by Bonferroni’s multiple comparisons test; *P < 0.05).

g) (Left) Number of CD11b+ in the SP of recipient mice that received Ctrl or MLL-Af4 transduced HSPCs from WT or I3KO mice at 14 weeks (one-way ANOVA followed by Bonferroni’s multiple comparisons test; **P < 0.01). (Right) Corresponding representative FACS plots showing CD11b+ and B220+ cells in the SP.